Leading Oncologist – Breast Cancer
Position: Former Director of the Oncology Institute
Hospital: Kaplan Medical Center in Rehovot
Dr. Noa Efrat Ben Baruch is a specialist in oncology. One of the leaders in advanced breast cancer treatment.
Qualified Medical Consultation Online, Second Opinion
Qualified Medical Consultation
- Early and Metastatic stages of: Breast Cancer
- HER2-mutated breast cancer
- New Diagnostics Protocols for Breast Cancer
- Oncotests
- Advanced breast cancer treatment
- Microinvasive Surgery
- Chemotherapy
- Radiation therapy
- Hormone therapy
Send Your Medical Files Book Consultation Now
Prof. Noa Ben Baruch’s private consultation and second opinion are given to patients after getting to know them in depth and in accordance with their personal and clinical state of their disease and their medical history, and with maximum attention to every detail.
Education
- Dr. Ben Baruch is a graduate of the Faculty of Medicine of the Ben Gurion University of the Negev and also has a bachelor’s degree in life sciences on behalf of laboratories at national institutes at MIT Cambridge University in the United States.
- In 1984 Internship in clinical and radiation oncology at the Sharett Institute at the Hadassah Ein Kerem Hospital
- Superspecialization in oncology at the National Cancer Institute in Maryland, USA
Experience of Dr. Ben Baruch
- Extensive experience in clinical and applied laboratory research at National Cancer Institutes of the United States: NCI – Bethesda, Maryland USA
- Former director of the Oncology Institute in Kaplan
- Performed clinical and applied laboratory studies at National Cancer Institutes of the United States: NCI – Bethesda, Maryland USA
Scientific Research and Treatment Discoveries
Dr. Noa Efrat Ben Baruch has been involved in several clinical trials, particularly focusing on breast cancer treatments. Here are a couple of notable trials:
HER2-Mutated Breast Cancer Treatment: Dr. Ben Baruch participated in a clinical trial investigating the efficacy of Neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor, for treating HER2-mutated breast cancer. This study was published in the Journal of the National Comprehensive Cancer Network1.
HR-positive/HER2-negative Metastatic Breast Cancer: She also contributed to research examining the role of chemotherapy in the evolving treatment landscape for patients with HR-positive/HER2-negative metastatic breast cancer2.
You can find more details about these trials through the following links:
- HER2-Mutated Breast Cancer Treatment – https://jnccn.org/view/journals/jnccn/13/9/article-p1061.xml
- HR-positive/HER2-negative Metastatic Breast Cancer – https://www.clinical-breast-cancer.com/article/S1526-8209%2821%2900301-3/pdf
Professional Organizations
- American Society of Oncology (ASCO)
- European Society of Oncology (ESMO)
- The Israeli Association for Clinical and Radiation Oncology (ISCORT)
